For fiscal 2025 (ended Dec 31, 2025), 20/20 Biolabs Inc. reported $2.05M of revenue and -$3.74M of net income.
AIDX revenue was $730.6K in fiscal Q2 2026 (ended Jun 30, 2026), up 36.5% from a year earlier and up 106.7% from the prior quarter. For the full fiscal 2025 it was $2.05M, up 16.7% from fiscal 2024.
AIDX net income was -$1.51M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$840.9K a year earlier. For the full fiscal 2025 it was -$3.74M, compared with -$5.55M in fiscal 2024.
AIDX diluted EPS was -$0.26 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.76, compared with -$1.16 in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | $2.05M | $1.75M |
| Cost of revenue | $1.44M | $1.39M |
| Gross profit | $604.5K | $360.3K |
| Research and development | $592.6K | $1.26M |
| Selling, general and admin | $3.34M | $4.76M |
| Operating income | -$3.33M | -$5.68M |
| Interest expense | $156.2K | $12.6K |
| Net income | -$3.74M | -$5.55M |
| EPS, basic | -$0.76 | -$1.16 |
| EPS, diluted | -$0.76 | -$1.16 |
| Diluted shares | 4.9M | 4.8M |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $1.03M | $1.78M |
| Receivables | $200.0K | $135.3K |
| Inventory | $116.2K | $47.2K |
| Current assets | $1.47M | $2.03M |
| Total assets | $4.14M | $3.58M |
| Current liabilities | $2.46M | $1.36M |
| Long-term debt | $619.4K | - |
| Total debt | $619.4K | - |
| Total liabilities | $4.16M | $2.08M |
| Shareholders' equity | -$19.2K | $1.51M |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$1.92M | -$2.60M |
| Financing cash flow | $1.16M | $293.3K |
| Stock-based compensation | $516.2K | $2.18M |
| Depreciation and amortization | $63.3K | $116.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Revenue | $730.6K | $353.4K | $535.1K | $553.8K |
| Cost of revenue | $425.8K | $290.5K | $371.8K | $388.0K |
| Gross profit | $304.7K | $62.9K | $163.3K | $165.8K |
| Research and development | $257.6K | $153.5K | $194.1K | $136.8K |
| Selling, general and admin | $1.29M | $1.35M | $814.8K | $801.1K |
| Operating income | -$1.24M | -$1.44M | -$845.7K | -$772.2K |
| Interest expense | $272.2K | $267.0K | $935 | $740 |
| Net income | -$1.51M | -$2.17M | -$840.9K | -$764.6K |
| EPS, basic | -$0.26 | -$0.28 | -$0.17 | -$0.16 |
| EPS, diluted | -$0.26 | -$0.28 | -$0.17 | -$0.16 |
| Diluted shares | 10.8M | 7.7M | 4.8M | 4.8M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and equivalents | $4.55M | $4.22M | $1.02M | $1.56M |
| Receivables | $291.5K | $201.5K | - | - |
| Inventory | $111.0K | $104.5K | - | - |
| Current assets | $5.08M | $4.70M | - | - |
| Total assets | $6.12M | $5.80M | - | - |
| Current liabilities | $2.55M | $2.58M | - | - |
| Total liabilities | $2.96M | $3.05M | - | - |
| Shareholders' equity | $1.62M | $2.55M | $351.6K | $1.06M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Operating cash flow | -$605.5K | -$1.29M | -$534.1K | -$488.3K |
| Investing cash flow | -$7.5K | -$5.4K | - | - |
| Financing cash flow | $940.0K | $4.49M | $0 | $262.3K |
| Stock-based compensation | $371.3K | $128.4K | $129.7K | $129.7K |
| Depreciation and amortization | $12.3K | $12.3K | $15.5K | $17.8K |
Source: XBRL data 20/20 Biolabs Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AIDX | $2.05M | +16.7% | -$3.74M | -182.8% | $2.6M |
| ULS | $3.19B | +6.1% | $513.00M | 16.1% | $16.39B |
| NEO | $787.75M | +11.1% | -$32.30M | -4.1% | $2.28B |